Dr. Smith's Dashboard

Sunovion Services

Request complimentary samples of LATUDA® (lurasidone HCl) tablets for your patients

ORDER YOUR SAMPLES NOW

Need support? Ask Sunovion Answers for information about LATUDA® (lurasidone HCl)

 

A dedicated team is available 7 days a week, from 8 AM to 12:00 midnight ET, to answer patient's calls at 1-855-552-8832

LEARN MORE

Most Viewed

Featured Expert Videos, Newsletters and Podcast on Bipolar Depression and LATUDA

In this section, expert clinicians share their insights on managing patients with bipolar depression.

 

Featured Content and Speakers

Featured experts are paid consultants of Sunovion.

Watch these videos for important insights into bipolar depression and LATUDA


icon-video-stahl
icon-video-stahl

Dr. Stephen M. Stahl

Dr. Stahl, Professor of Psychiatry, University of California, San Diego, presents a series of videos that share his perspectives on bipolar depression, how it typically manifests, and the challenges of diagnosis.

See videos

icon-video-mcintyre
icon-video-mcintyre

Dr. Roger S. McIntyre

Get information about bipolar depression from Dr. Roger S. McIntyre, Professor of Psychiatry and Pharmacology at the University of Toronto and Head of the Mood Disorders Psychopharmacology Unit at the University Health Network in Toronto, Canada.

See video

icon-video-leblanc
icon-video-leblanc

Nurse Practitioner Tammy LeBlanc

Get insights into bipolar depression from a Nurse Practitioner perspective. Tammy LeBlanc, NP talks about bipolar disorder as well as collaborative care for patients with bipolar depression.

See videos

icon-video-jain
icon-video-jain

Dr. Rakesh Jain

Review a case study involving the evaluation and treatment of bipolar depression presented by Dr. Rakesh Jain, Clinical Professor in the Department of Psychiatry at Texas Tech University School of Medicine in Midland, Texas.

See video

icon-video-calabrese
icon-video-calabrese

Dr. Joseph R. Calabrese

In this video series, watch Dr. Joseph R. Calabrese, an expert in the field of mood disorders, discuss the challenges doctors face in diagnosing and treating patients with bipolar disorder and review specifics about LATUDA.

See videos

icon-video-moa
icon-video-moa

LATUDA Proposed Mechanism of Action

See how LATUDA is thought to work in relation to the brain neurotransmitters dopamine and serotonin. Although the mechanism of action (MOA) of LATUDA is unknown, this video presents a potential MOA for the treatment of bipolar depression.

See video

Dr. Stephen M. Stahl
 
Interviewing can provide a new perspective on Mark's breakthrough symptoms
Mark's medication history and struggles with symptom control
Mark's success from a collaborative care approach
The history behind Nora's misdiagnosis
Nora's symptoms point toward bipolar depression
Nora's diagnosis of bipolar depression
By the Book: Diagnosis of Bipolar Depression
Identifying Bipolar Depression is Challenging
Mixed Messages
Dr. Roger S. McIntyre
 
What is Bipolar Depression?
Nurse Practitioner Tammy LeBlanc
 
Is it Bipolar Disorder?
Collaborative Care
Dr. Rakesh Jain
 
A Case-Based Exploration of Identifying and Treating Bipolar Depression
Dr. Joseph R. Calabrese
 
Chapter 1: Bipolar Disorder Diagnosis and Treatment Challenges
Chapter 2: Study Design
Chapter 3: Efficacy
Chapter 4: Safety and Tolerability
Chapter 5: Metabolic Parameters
Chapter 6: Dosing
LATUDA Proposed Mechanism of Action Video
 
See How LATUDA is Thought to Work

Featured Newsletters

Review these newsletters for expert perspectives on bipolar depression and LATUDA.


Nurse Practitioners and Physician Assistants

 

Bipolar Depression: The Search for Diagnosis and Treatment

Susan J. Barnes, APRN-BC, and Diane M. Snow PhD, APRN, PMHNP-BC, FAANP, FIANN






Download
Engaging Patients to Support Adherence

Vivien K Burt, MD, PhD, Catherine R. Judd, MS, PA-C, CAQ-Psychiatry, DFAAPA, and Mauricio Tohen, MD, DrPH, MBA





Download
Bipolar Depression Diagnosis: Confounding Factors

Anna M. O'Kinsky, MSN, APN, and Diane M. Snow PhD, APRN, PMHNP-BC, FAANP, FIANN






Download
Bipolar Depression:
A Collaborative Approach to Care


Danielle L. Kamine, MS, ARNP, ANP-BC, CARN-AP, PMHNP-BC, and Diane M. Snow, PhD, APRN, PMHNP-BC, FAANP, FIAAN




Download
Are You Up to Date? Latest Guidance for Evidence-Based Treatment for Bipolar Depression

William Clay Jackson, MD, DipTH, FAAFP, Susan L. Kraus, MSN, MAgS, CRNP-A, CRNP-PMH, Henry A. Nasrallah, MD, and Diane M. Snow, PhD, APRN, PMHNP-BC, FAANP, FIAAN


Download

Psychiatrists

Bipolar Depression: The Search for Diagnosis and Treatment

James Sloan Manning, MD, and Henry A. Nasrallah, MD







Download
Managing Multiple Comorbidities in Bipolar Disorder

Larry Culpepper, MD, MPH, Andrew J. Cutler, MD, James Sloan Manning, MD, and Anna M. O'Kinsky, MSN, APN





Download
Bipolar Depression Diagnosis: Confounding Factors

Vivien K. Burt, MD, PhD, and Henry A. Nasrallah, MD







Download
Are You Up to Date? Latest Guidance for Evidence-Based Treatment for Bipolar Depression

William Clay Jackson, MD, DipTh, FAAFP, Susan L. Kraus, MSN, MAgS, CRNP-A, CRNP-PMH, Henry Nasrallah, MD, and Diane M. Snow, PhD, APRN, PMHNP-BC, FAANP, FIAAN


Download
Engaging Patients to Support Adherence

Vivien K. Burt, MD, PhD, Catherine R. Judd, MS, PA-C, CAQ-Psychiatry, DFAAPA, and Mauricio Tohen, MD, DrPH, MBA





Download

Primary Care Physicians

Bipolar Depression: The Search for Diagnosis and Treatment

James Sloan Manning, MD, and Henry A. Nasrallah, MD







Download
Are You Up to Date? Latest Guidance for Evidence-Based Treatment for Bipolar Depression

William Clay Jackson, MD, DipTH, FAAFP, Susan L. Kraus, MSN, MAgS, CRNP-A, CRNP-PMH, Henry A. Nasrallah, MD, and Diane M. Snow, PhD, APRN, PMHNP-BC, FAANP, FIAAN


Download
Bipolar Depression in Primary Care: A Collaborative Approach

William Clay Jackson, MD, DipTH, FAAFP, and Henry A. Nasrallah, MD







Download
Managing Multiple Comorbidities in Bipolar Disorder

Larry Culpepper, MD, MPH, Andrew J. Cutler, MD, James Sloan Manning MD, and Anna M O'Kinsky, MSN, APN





Download
Engaging Patients to Support Adherence

Vivien K. Burt, MD, PhD, Catherine R. Judd, MS, PA-C, CAQ-Psychiatry, DFAAPA, and Mauricio Tohen, MD, DrPH, MBA





Download

Featured Podcast

Family physician James Sloan Manning, MD, describes the 4 key principles of motivational interviewing and explains how this technique may help clinicians elicit information from patients with bipolar depression.

James Sloan Manning, MD Motivational Interviewing

IMPORTANT SAFETY INFORMATION AND INDICATIONS FOR LATUDA

INCREASED MORTALITY IN ELDERLY PATIENTS WITH DEMENTIA-RELATED PSYCHOSIS; and SUICIDAL THOUGHTS AND BEHAVIORS

Increased Mortality in Elderly Patients with Dementia-Related Psychosis
Elderly patients with dementia-related psychosis treated with antipsychotic drugs are at an increased risk of death. LATUDA is not approved for the treatment of patients with dementia-related psychosis.

Suicidal Thoughts and Behaviors
Antidepressants increased the risk of suicidal thoughts and behaviors in patients aged 24 years and younger. Monitor for clinical worsening and emergence of suicidal thoughts and behavior. LATUDA is not approved for use in pediatric patients with depression.

 

CONTRAINDICATIONS: LATUDA is contraindicated in the following:

Cerebrovascular Adverse Reactions, Including Stroke: In clinical trials, elderly subjects with dementia randomized to risperidone, aripiprazole, and olanzapine had a higher incidence of stroke and transient ischemic attack, including fatal stroke. LATUDA is not approved for the treatment of patients with dementia-related psychosis.

Neuroleptic Malignant Syndrome (NMS): NMS is a potentially fatal symptom complex, reported with administration of antipsychotic drugs. Clinical signs of NMS are hyperpyrexia, muscle rigidity, altered mental status, and evidence of autonomic instability. Additional signs may include elevated creatine phosphokinase, myoglobinuria (rhabdomyolysis), and acute renal failure. Manage NMS with immediate discontinuation of antipsychotic drugs, including LATUDA, intensive symptomatic treatment, and monitoring.

Tardive Dyskinesia (TD): The risk of developing TD (a syndrome of abnormal involuntary movements) and the potential for it to become irreversible are believed to increase as the duration of treatment and total cumulative dose of antipsychotic increase. The syndrome can develop, although much less commonly, after relatively brief treatment periods at low doses. There is no known treatment for established TD, although the syndrome may remit, partially or completely, if antipsychotic treatment is withdrawn.

Metabolic Changes Atypical antipsychotic drugs have caused metabolic changes including:

Hyperglycemia and Diabetes Mellitus: Hyperglycemia, in some cases extreme and associated with ketoacidosis or hyperosmolar coma or death, has been reported in patients treated with atypical antipsychotics. Patients with diabetes should be regularly monitored for worsening of glucose control; those with risk factors for diabetes should undergo fasting blood glucose testing at the beginning of and periodically during treatment. Any patient treated with atypical antipsychotics should be monitored for symptoms of hyperglycemia including polydipsia, polyuria, polyphagia, and weakness. Patients who develop symptoms of hyperglycemia should undergo fasting blood glucose testing. In some cases, hyperglycemia has resolved when the atypical antipsychotic was discontinued; however, some patients required continuation of anti-diabetic treatment despite discontinuation of the suspect drug.

Dyslipidemia: Undesirable alterations in lipids have been observed in patients treated with atypical antipsychotics.

Weight Gain: Weight gain has been observed with atypical antipsychotic use. Clinical monitoring of weight is recommended.

Hyperprolactinemia: As with other drugs that antagonize dopamine D2 receptors, LATUDA elevates prolactin levels. Galactorrhea, amenorrhea, gynecomastia, and impotence have been reported in patients receiving prolactin-elevating compounds.

Leukopenia, Neutropenia, and Agranulocytosis: Leukopenia/neutropenia has been reported with antipsychotics. Agranulocytosis (including fatal cases) has been reported with other agents in the class. Monitor complete blood count in patients with a pre-existing low white blood cell count (WBC)/absolute neutrophil count (ANC) or history of drug-induced leukopenia/neutropenia. Discontinue LATUDA at the first sign of a decline in WBC in the absence of other causative factors.

Orthostatic Hypotension and Syncope: Atypical antipsychotics cause orthostatic hypotension and syncope. Generally, the risk is greatest at the beginning of treatment and when increasing the dose. Monitor patients vulnerable to hypotension and those with cardiovascular and cerebrovascular disease.

Falls: Antipsychotics may cause somnolence, postural hypotension, motor and sensory instability, which may lead to falls causing fractures or other injuries. For patients with disease, conditions, or medications that could exacerbate these effects, complete fall risk assessments when initiating treatment and recurrently during therapy.

Seizures: LATUDA should be used cautiously in patients with a history of seizures or with conditions that lower seizure threshold.

Potential for Cognitive and Motor Impairment: Patients should be cautioned about operating hazardous machinery, including motor vehicles, until they are reasonably certain that therapy with LATUDA does not affect them adversely.

Body Temperature Regulation: Use LATUDA with caution in patients who may experience conditions that increase body temperature (e.g., exercising strenuously, exposure to extreme heat, concomitant medication with anticholinergic activity, or being subject to dehydration).

Dysphagia: Antipsychotics, including LATUDA, have been associated with esophageal dysmotility and aspiration, and should be used with caution in patients at risk for aspiration pneumonia.

Most Commonly Observed Adverse Reactions: Commonly observed adverse reactions (≥5% incidence and at least twice the rate of placebo) for LATUDA:

To report SUSPECTED ADVERSE REACTIONS, contact Sunovion Pharmaceuticals Inc. at 877-737-7226 or FDA at 1-800-FDA-1088 (www.fda.gov/medwatch).

Indications

LATUDA is indicated for:

Before prescribing LATUDA, please read the full Prescribing Information, including Boxed Warnings.